1
Highly sensitive detection of TB from sputum samples. Accurate diagnosis from a single drop of blood. Drug susceptibility tests that allow right first-time prescribing. 1/4 Tuberculosis (TB) may sound like a thing of the past. But it is one of the biggest challenges facing global health providers today. Every year, there are 10.4 million new cases and 1.7 million deaths. 1 Most of these deaths could be prevented with early diagnosis and appropriate treatment. However, at the current rate of progress, the World Health Organisation’s End TB Strategy will not achieve its goal to reduce 95% of TB deaths by 2035. 2 4.3 million people with TB are ‘missed’ by healthcare systems every year. 3 Over 95% of TB cases and deaths are in developing countries 1 where many people don’t live within walking distance of a healthcare facility. Access difficulties are compounded by poverty, conflict, and the stigma of seeking TB treatment in areas closely associated with HIV infection. Studies have shown that up to 38% of tested patients were lost to follow-up before treatment even began. 4 About one-quarter of the world's population has latent TB infection, which means they are infected with TB bacteria but do not feel ill. 1 However, without treatment, up to 10% will develop active TB disease in the future. 5 Most are not accessing preventative treatment. Each person with active TB can infect another 10–15 people a year. 1 TACKLING CHALLENGES TO ENDING TB QuantuMDx: In the front line of the fight to end TB ACCESS TO HEALTHCARE LATENT TB MULTI-DRUG RESISTANT TB Multi-drug resistant TB (MDR-TB) is a major health problem. This is TB that doesn’t respond to the most important ‘frontline’ TB drugs, Isoniazid and Rifampicin. In 2016, 490,000 people developed MDR-TB. 6 Only 1 in 4 MDR cases is diagnosed 7 and MDR patients infect others with MDR-TB. Extensively drug resistant TB (XDR-TB) is a form of TB which is resistant to at least four of the core anti-TB drugs. Globally, it’s estimated that approximately 70% of XDR-TB patients die within a month of diagnosis. 8 The WHO’s End TB target will only be achieved by making effective diagnosis and treatment universally available. The first step will be working collaboratively to speed up the global launch of affordable diagnostic tools. QuantuMDx is working with the TB community to deliver accurate, accessible diagnostic solutions that patients need. Our partners include: FIND, the Bill and Melinda Gates Foundation, The Stop TB Partnership and St George’s, University of London. QuantuMDx is developing two next-generation molecular diagnostic platforms – Capture-XT™ and Q-POC™ - which aim to revolutionise point of care testing for all forms of TB, all ages and immune status. Early and accurate diagnosis and detection of drug-sensitive and drug-resistant tuberculosis is essential for achieving global tuberculosis control The Lancet, March 23, 2018 “ ” Brought to you by quantumdx.com 1. www.who.int/news-room/fact-sheets/detail/tuberculosis 2. www.who.int/tb/post2015_strategy/en/ 3. www.cdc.gov/globalhivtb/who-we-are/resources/keyareafactsheets/ finding-the-missing-4-million.pdf 4. Peter MacPherson, Ren MGJ Houben, Judith R Glynn, Elizabeth L Corbett, Katharina Kranzer. Pre-treatment loss to follow-up in tuberculosis patients in low- and middle-income countries and high-burden countries: a systematic review and meta-analysis. 5. Finding the missing TB cases, Dr Malgosia Grzemska, WHO, October 2017 6. www.who.int/features/qa/79/en/ 7. www.stoptb.org/events/world_tb_day/2016/assets/docs/ EndTB_Infographic_GENERAL.jpg 8. www.tbalert.org/about-tb/global-tb-challenges/drug-resistant-tb/ 95 % live in low resource countries 4 . 3 m cases missed 3 8 % lost to follow-up has latent TB 10 % develop active TB 10-15 others infected 490 k have MDR-TB 3/4 MDR cases are missed 7 0 % XDR patients die rapidly M U L T I - D R U G R E S I S T A N T T B L A T E N T T B
